Meningococcal C vaccination is cost effective

The meningococcal C vaccination campaign, launched in November 1999, has rapidly reduced the incidence of serotype C meningococcal disease in the target age groups. Using cost effectiveness analysis, Trotter and Edmunds (p 809) estimate the cost per life saved to be £6259 and find vaccination to be most cost effective when the incidence of the disease is high. School based vaccination is more cost effective than the routine vaccination of infants because delivery costs are lower and fewer doses are required. Immunisation of infants aged under 1 year was least cost effective, as a three dose schedule is required.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales
Caroline L Trotter and W John Edmunds
BMJ 2002 324: 809. [Abstract] [Full Text] [PDF]

Access all current jobs at BMJ Group
Whats new online at Student BMJ
Listen to the latest BMJ Interview